Memezawa H, Katayama Y, Shimizu J, Suzuki S, Kashiwagi F, Kamiya T, Terashi A
Second Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Adv Neurol. 1990;52:109-18.
Perfluorochemicals were developed as a blood substitute and were reported to have an advantage in oxygen transport compared with blood. The present study was undertaken to investigate the therapeutic effects of a perfluorochemical, FDA, on brain edema and metabolites in acute cerebral ischemia. Cerebral ischemia was induced in SHR by BLCO followed by recirculation. The FDA administration resulted in (a) the significant inhibition of brain edema as shown by brain water content in the treated group, and (b) significant amelioration of metabolic impairments as shown by lesser degree of ATP and pyruvate decrease and lactate accumulation. The TpO2 was compared between FDA-infused and nontreated group during ischemia. The FDA-infused group had significantly higher TpO2 than nontreated group. These results indicate that the improvement of brain edema and metabolite levels were due to alleviation of ischemic hypoxia by FDA under the same ischemic insult.
全氟化合物被开发用作血液替代品，据报道与血液相比，其在氧气运输方面具有优势。本研究旨在探讨一种全氟化合物FDA对急性脑缺血后脑水肿和代谢物的治疗作用。通过大脑中动脉闭塞（BLCO）诱导自发性高血压大鼠（SHR）发生脑缺血，随后进行再灌注。给予FDA导致：（a）治疗组脑含水量显示脑水肿得到显著抑制；（b）ATP和丙酮酸减少程度较轻以及乳酸积累减少，显示代谢障碍得到显著改善。在缺血期间比较了注入FDA组和未治疗组的脑组织氧分压（TpO2）。注入FDA组的TpO2显著高于未治疗组。这些结果表明，在相同的缺血损伤下，脑水肿和代谢物水平的改善是由于FDA减轻了缺血性缺氧。
